Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05844423 · ClinicalTrials.gov registry record · Phase 2

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

A Phase 2 study of Pneumococcal Vaccines, sponsored by Vaxcyte.

Completed
Registry status
Phase 2
Development phase
802
Enrollment target
20
Study locations

NCT05844423 is a Phase 2 study of Pneumococcal Vaccines that has completed, run by Vaxcyte. The registered enrollment target is 802 participants, below the 1,426-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05844423, a Phase 2 study of Pneumococcal Vaccines, has completed, sponsored by Vaxcyte.

COMPLETED
Registry status
Phase 2
Development phase
802 participants
Enrollment target
20
Study locations

Study Summary

The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.

Conditions Studied

Pneumococcal Vaccines

Interventions

  • BIOLOGICAL 0.5 ml dose of 1.1 mcg VAX-24
  • BIOLOGICAL 0.5 ml dose of PCV20
  • BIOLOGICAL 0.5 ml dose of 2.2 mcg VAX-24
  • BIOLOGICAL 0.5 ml dose of 2.2/4.4 mcg VAX-24

Study Locations (20)

Pennsylvania

  • UPMC Bass Wolfson Cranberry - Cranberry Township
  • Allegheny Health and Wellness Pavilion - Erie
  • UPMC Children's Community Pediatrics South Hills-Jefferson Hills - Jefferson Hills
  • UPMC Primary Care Center Oakland - Pittsburgh
  • UPMC Children's Community Pediatrics Bass Wolfson-Squirrel Hill - Pittsburgh
  • UPMC Children's Community Pediatrics-Castle Shannon - Pittsburgh

Nebraska

  • Meridian Clinical Research - Hastings
  • Midwest Children's Health Research Institute - Lincoln
  • Midwest Children's Health Research Institute - Lincoln
  • Midwest Children's Health Research Institute - Lincoln
  • Midwest Children's Health Research Institute - Lincoln

South Carolina

  • Palmetto Pediatrics, PA - North Charleston
  • Tribe Clinical Research at Parkside Pediatrics - Simpsonville
  • Coastal Pediatric Research - Summerville

Arkansas

  • The Children's Clinic of Jonesboro, P.A. - Jonesboro

California

  • Madera Family Medical Group - Madera

Florida

  • Jedidiah Clinical Research - Tampa

Kentucky

  • Kentucky Pediatric/ Adult Research - Bardstown

Louisiana

  • ACC Pediatric Research - Haughton

Trial Details

FieldValue
Enrollment Target 802 participants
Start Date 2023-03-29
Est. Completion 2025-08-25
Phase Phase 2

Sponsor

Vaxcyte

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05844423

The ClinicalTrials.gov registry entry for NCT05844423 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 802 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,426-participant average among 5 other Pneumococcal Vaccines trials with a reported enrollment target (44% lower). The listed sponsor is Vaxcyte, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pneumococcal Vaccines appearing as the primary indexed condition, and to 4 interventions - of which 0.5 ml dose of 1.1 mcg VAX-24 is the first listed.

NCT05844423 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Pennsylvania, Nebraska, South Carolina.

Frequently Asked Questions

What is clinical trial NCT05844423 about?

NCT05844423 is a clinical study titled "Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants". The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. ...

What is the current status of trial NCT05844423?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 802 participants. The study started on 2023-03-29. Estimated completion is 2025-08-25.

What conditions does trial NCT05844423 study?

This clinical trial studies the following conditions: Pneumococcal Vaccines.

What interventions are being tested in trial NCT05844423?

The interventions under investigation include: 0.5 ml dose of 1.1 mcg VAX-24 (BIOLOGICAL), 0.5 ml dose of PCV20 (BIOLOGICAL), 0.5 ml dose of 2.2 mcg VAX-24 (BIOLOGICAL), 0.5 ml dose of 2.2/4.4 mcg VAX-24 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05844423?

This trial is sponsored by Vaxcyte, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05844423 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pneumococcal Vaccines

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pneumococcal Vaccines

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.